Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms
Authors
Keywords
Coumarin anticoagulant, Pharmacogenetics, Warfarin, Cytochrome P450, Vitamin K epoxide reductase
Journal
ARCHIVES OF TOXICOLOGY
Volume 87, Issue 3, Pages 407-420
Publisher
Springer Nature
Online
2013-02-02
DOI
10.1007/s00204-013-1013-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polymorphisms in VKORC 1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates
- (2012) Kirstin Lund et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
- (2012) Jeffrey L. Anderson et al. CIRCULATION
- Decreased Warfarin Clearance Associated With the CYP2C9 R150H (*8) Polymorphism
- (2012) Y Liu et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users
- (2012) T. I. VERHOEF et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
- (2012) Jason D Roberts et al. LANCET
- Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population
- (2012) Addepalli Pavani et al. PHARMACOGENOMICS
- Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
- (2012) Joyce H. S. You et al. PLoS One
- Therapeutic Dosing of Acenocoumarol: Proposal of a Population Specific Pharmacogenetic Dosing Algorithm and Its Validation in North Indians
- (2012) Saurabh Singh Rathore et al. PLoS One
- An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease
- (2012) Alberto M. Borobia et al. PLoS One
- Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction
- (2012) Husam Qasim et al. THROMBOSIS AND HAEMOSTASIS
- A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: Derivation in Han Chinese patients with non valvular atrial fibrillation
- (2012) Meng Wei et al. THROMBOSIS AND HAEMOSTASIS
- Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
- (2012) Benjamin French et al. Trials
- Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy
- (2011) I. Y. Gong et al. BLOOD
- Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement
- (2011) C. Moreau et al. BLOOD
- VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children
- (2011) T. T. Biss et al. BLOOD
- Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione
- (2011) Karine Lacut et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes
- (2011) Rebecca Howard et al. CLINICA CHIMICA ACTA
- EPHX1 Polymorphisms Are Not Associated With Warfarin Response in an Italian Population
- (2011) C Ciccacci et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy
- (2011) P J Avery et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans
- (2011) M A Perera et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Development and Comparison of a Warfarin-Dosing Algorithm for Korean Patients With Atrial Fibrillation
- (2011) Hyun-Jung Cho et al. CLINICAL THERAPEUTICS
- Identification of Cytochrome P450 Oxidoreductase Gene Variants That Are Significantly Associated with the Interindividual Variations in Warfarin Maintenance Dose
- (2011) X. Zhang et al. DRUG METABOLISM AND DISPOSITION
- Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data
- (2011) Rianne M.F. van Schie et al. EUROPEAN HEART JOURNAL
- A randomized controlled trial of genotype-based Coumadin initiation
- (2011) James K Burmester et al. GENETICS IN MEDICINE
- Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans
- (2011) Larisa H. Cavallari et al. Pharmacogenetics and Genomics
- Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population
- (2011) Cathrine Mitchell et al. PHARMACOGENOMICS
- Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design
- (2011) E J Do et al. PHARMACOGENOMICS JOURNAL
- Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients
- (2011) Larisa H Cavallari et al. PHARMACOTHERAPY
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
- (2010) N. A. Limdi et al. BLOOD
- Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006)
- (2010) Pilar Carrasco-Garrido et al. BMC HEALTH SERVICES RESEARCH
- New genetic variant that might improve warfarin dose prediction in African Americans
- (2010) Hedi Schelleman et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Polymorphism in the VKORC1 Regulator Calumenin Predicts Higher Warfarin Dose Requirements in African Americans
- (2010) D Voora et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing
- (2010) P Lenzini et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese
- (2010) P.-C. Cha et al. HUMAN MOLECULAR GENETICS
- Warfarin Genotyping Reduces Hospitalization Rates
- (2010) Robert S. Epstein et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Genome-wide association studies in pharmacogenomics
- (2010) Ann K. Daly NATURE REVIEWS GENETICS
- Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population
- (2010) Sze Ling Chan et al. Pharmacogenetics and Genomics
- Gene-Based Warfarin Dosing Compared With Standard of Care Practices in an Orthopedic Surgery Population: A Prospective, Parallel Cohort Study
- (2010) Gwendolyn A McMillin et al. THERAPEUTIC DRUG MONITORING
- Gamma-glutamyl carboxylase and its influence on warfarin dose
- (2010) Cristi King et al. THROMBOSIS AND HAEMOSTASIS
- Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1 , F7 , GGCX , CALU , EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy
- (2010) B. Luxembourg et al. THROMBOSIS AND HAEMOSTASIS
- Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
- (2009) N.A. Limdi et al. BLOOD CELLS MOLECULES AND DISEASES
- Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients
- (2009) E Pautas et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A genome-wide association study of acenocoumarol maintenance dosage
- (2009) Martina Teichert et al. HUMAN MOLECULAR GENETICS
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant
- (2009) M. G. McDonald et al. MOLECULAR PHARMACOLOGY
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study
- (2009) Andrea L. Jorgensen et al. Pharmacogenetics and Genomics
- Genetic determinants of warfarin dosing in the Han-Chinese population
- (2009) MT Michael Lee et al. PHARMACOGENOMICS
- Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
- (2009) Rianne MF van Schie et al. PHARMACOGENOMICS
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
- (2009) Fumihiko Takeuchi et al. PLoS Genetics
- Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations
- (2008) Stuart A. Scott et al. AMERICAN JOURNAL OF HUMAN GENETICS
- CYP4F2 genetic variant alters required warfarin dose
- (2008) M. D. Caldwell et al. BLOOD
- VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals
- (2008) E. Aklillu et al. BLOOD
- Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
- (2008) D. Wang et al. BLOOD
- The largest prospective warfarin-treated cohort supports genetic forecasting
- (2008) M. Wadelius et al. BLOOD
- A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
- (2008) G. M. Cooper et al. BLOOD
- Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions inVKORC1
- (2008) D. J. HARRINGTON et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations
- (2008) Alan HB Wu et al. PHARMACOGENOMICS
- Influence ofCYP2C9andVKORC1on warfarin dose, anticoagulation attainment and maintenance among European–Americans and African–Americans
- (2008) Nita A Limdi et al. PHARMACOGENOMICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More